Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000139:chemically induced; D003872:Dermatitis / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D000470:Alkaloids; D000970:Antineoplastic Agents